Aragon Pharmaceuticals has announced the dosing of the first patient in its Phase I study of ARN-810 in estrogen receptor-positive breast cancer.
The Phase I dose escalation study, which will be conducted at Vanderbilt University, Mass General Hospital and Memorial Sloan-Kettering Cancer Center, will assess the safety and tolerability of ARN-810.
Go deeper with GlobalData
ARN-810 is an oral selective estrogen receptor degrader (SERD) designed to treat locally advanced or metastatic estrogen receptor-positive breast cancer in post-menopausal women.
The nonsteroidal agent degrades the receptor by binding to the estrogen receptor, inducing a conformational change.
Aragon Pharmaceuticals CEO Richard Heyman said ARN-810 is the most advanced candidate in its novel SERD programme.
"Today’s announcement represents a landmark step for us, as our SERD program originated within Aragon and is wholly-owned," Heyman said.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData"We are hopeful that ARN-810’s novel approach to breast cancer therapy will prove to be a more effective, sustained treatment option for this important patient population."
The Vanderbilt-Ingram Cancer Center clinical research associate director and breast cancer programme director Dr Carlos Arteaga said; "This drug may become another treatment option for many women with breast cancer."
